← Leaderboards
Gilbert Gallardo
Washington University
$3,015,401
Attributed
$3,015,401
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $785.1K · FY2016–23$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,015,401 · 3
By mechanism
R01$1,967,291 · 1
K01$655,506 · 1
R56$392,604 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Robert W Mercer$2,271,259
- David M Holtzman$51,909,630
- Marc R Hammerman$10,095,003
- R W Mercer$122,928
- Gregory A Ewald$1,047,165
Others in their field
Top investigators on “Dependovirus”
- Michael R. Farzan · Boston Children'S Hospital$34,788,985
- Xiangmin Xu · University Of California-Irvine$20,054,174
- Ronald G Crystal · Weill Medical College Of Cornell Univ$19,424,144
- Krishanu Saha · University Of Wisconsin-Madison$16,865,384
- Mauricio De Aguiar Martins · University Of Florida$16,135,962
- Bing Ren · Ludwig Institute For Cancer Research$14,951,266
Research focus
DependovirusTauopathiesExtracellularChronicNeuronsBrainPathologyMediatingCellsPathogenesisPreventTau ProteinsImmunotherapeutic AgentAlzheimer&AposAntibodiesBlood - Brain Barrier AnatomyImmunotherapyEngineeringGene TransferPassive ImmunizationLysosomesNeurodegenerative DisordersPathologicTranslating
Grant awards (9)
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy$393,750
R01 · FY2023 · AG · contact PI
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy$393,750
R01 · FY2022 · AG · contact PI
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy$393,750
R01 · FY2021 · AG · contact PI
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy$393,541
R01 · FY2020 · AG · contact PI
Attenuating the Astrocytic ñ2-N/K-ATPase to Lessen the Impact of Neuroinflammation on Tauopathy and Amyloid Plaque Burden$392,604
R56 · FY2019 · NS · contact PI
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy$392,500
R01 · FY2019 · AG · contact PI
Advancing Antibody Technology for tau Immunotherapies and for Investigating tau Pathogenesis$218,502
K01 · FY2018 · NS · contact PI
Advancing Antibody Technology for tau Immunotherapies and for Investigating tau Pathogenesis$218,502
K01 · FY2017 · NS · contact PI
Advancing Antibody Technology for tau Immunotherapies and for Investigating tau Pathogenesis$218,502
K01 · FY2016 · NS · contact PI